Liposome formulation of vilanterol trifenatate
View Patent ↗The present invention is directed to a liposomal formulation comprising a lipid ingredient encapsulating vilanterol trifenatate, and a method for administering the liposomal formulation by nebulizing the liposomal formulation in an inhaler. The liposomal formulation comprises vilanterol or a salt thereof, and lipid ingredients comprising a pharmaceutical lipid and/or a sterol. The drug to lipid mass ratio is in the range of about 1:20 to about 1:100. Additionally, the present invention is directed to the use of the liposomal formulation for the prevention or treatment of respiratory diseases such as Chronic Obstructive Pulmonary Disease and/or asthma.
1. A formulation comprising a plurality of liposomes, wherein the liposomes comprise a lipid ingredient encapsulating vilanterol trifenatate, the lipid ingredient comprises a lipid and a sterol, and wherein the vilanterol trifenatate and lipid ingredient are present in a mass ratio of between about 1:10 and about 1:150 (vilanterol trifenatate:lipid ingredient).
2. The formulation according to claim 1 , wherein the liposomes have an average size of about 50 nm to about 500 nm.
3. The formulation according to claim 1 , wherein the lipid is selected from the group consisting of phosphatidylcholine (PC), phosphatidic acid (PA), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphatidylserine (PS), phosphatidylinositol (PI), dimyristoyl phosphatidyl choline (DMPC), distearoylphosphatidyl choline (DSPC), dipalmitoyl phosphatidyl choline (DPPC), dimyristoyl phosphatidyl glycerol (DMPG), distearoylphosphatidyl glycerol (DSPG), dioleoyl phosphatidyl glycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dimyristoyl phosphatidyl serine (DMPS), distearoyl phosphatidyl serine (DSPS), dioleoyl phosphatidyl serine (DOPS), dipalmitoyl phosphatidyl serine (DPPS), dioleoyl phosphatidyl ethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyp-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidylethanolamine (DSPE), di stearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), and combinations thereof.
4. The formulation according to claim 1 , wherein the sterol is selected from the group consisting of cholesterol, ergosterol, lanosterol, and combinations thereof.
5. The formulation according to claim 1 , wherein the liposomes have a D50 value of less than about 10 μm.
6. The formulation according to claim 1 , further comprising an antioxidant selected from the group consisting of a water-soluble antioxidant and an oil-soluble antioxidant.
7. The formulation according to claim 1 , wherein the lipid ingredient comprises DPPC, DSPG, and cholesterol, in a molar ratio of about 9:1:5 (DPPC:DSPG:cholesterol).
8. The formulation according to claim 1 , wherein the lipid ingredient comprises DPPC and cholesterol, in a molar ratio of about 1:5 (DPPC:cholesterol).
9. A method for preparing a liposomal formulation, comprising: (1) preparing a vilanterol trifenatate solution, (2) preparing a lipid solution, (3) mixing the vilanterol trifenatate solution with the lipid solution to provide a mixture, and (4) extruding the mixture.
10. The method according to claim 9 , wherein the liposomal formulation has a pH of about 4.0 to about 7.5.
11. The method according to claim 9 , wherein the lipid solution comprises a lipid ingredient, and wherein the vilanterol trifenatate and the lipid ingredient are present in a mass ratio that ranges from about 1:10 to about 1:150.
12. The method according to claim 9 , wherein the extruding is carried out at a temperature between about 60° C. and about 70° C.